Ample evidence suggests that a key event in the etiology of Alzheimer's disease is the excessive production of β amyloid peptide (Aβ) and its extracellular deposition; deregulation of neuronal metabolism and signaling cascades ensues 1 . Large Aβ aggregates, also called fibrils, form characteristic amyloid plaques in the brains of individuals with Alzheimer's disease. These plaques have long been viewed as highly cytotoxic, but many recent studies indicate that smaller soluble forms of Aβ may be the true culprits causing neuronal injury 2 .
The biochemistry of Aβ toxicity is a work in progress-however, multiple lines of evidence suggest that mitochondria are among the important or even major intracellular targets of soluble Aβ oligomers. Soluble Aβ localizes to mitochondria and interferes with their normal functioning, causing overproduction of reactive oxygen species (ROS), inhibiting respiration and ATP production and damaging the structure of mitochondria 3 .
It is quite possible that the deleterious effects of Aβ on mitochondria result from disruption of intracellular calcium homeostasis and signaling ( Fig. 1) , which is another signature aspect of Aβ toxicity. Abnormally high cytosolic calcium levels and deregulated calcium signaling occur in neurites proximal to Aβ plaques 4 . Moreover, Aβ oligomers (but not fibrils) induce massive calcium entry into cultured neurons, mitochondrial calcium overload and apoptosis of neurons-all preventable if mitochondria are not allowed to accumulate excess calcium. The calcium overload of mitochondria results in the opening of the mitochondrial permeability transition pore (mPTP) 5 , a large channel in the inner mitochondrial membrane. Its opening allows uncontrolled bidirectional passage of large molecules, which results in the functional and structural disintegration of mitochondria-akin to an activation of a natural selfdestruction facility built into the complicated mitochondrial fabric.
In this issue of Nature Medicine, Du et al. 6 present compelling evidence that Aβ targets the mPTP and amplifies calciuminduced mitochondrial damage. They find that inhibiting the mPTP ameliorates cognitive deficiencies in a transgenic mouse model of Alzheimer's disease 6 . Furthermore, the authors prove that Aβ oligomers target the mitochondrial protein cyclophilin D (CypD), a well known regulator of mPTP 6 .
The mPTP has been studied for more than 40 years but remains enigmatic. It is drawing tremendous interest now because of its suggested role in cell death induced by ischemia, trauma and various neurodegenerative diseases 7, 8 . Aβ Figure 1 Mitochondria in Alzheimer's disease. In nondiseased neurons, the mPTP is closed, and mitochondria produce ATP and maintain other functions. Cytosolic calcium levels are kept low via ATPdependent sequestration into endoplasmic reticulum (ER), ATP-dependent extrusion through the Ca 2+ -ATPase of the plasma membrane (not shown) and energy-dependent sequestration into mitochondria. However, in neurons affected with Alzheimer's disease, an accumulation of soluble Aβ results in elevated cytosolic calcium levels owing to leaks from Aβ-modified calcium-conducting channels in then e w s a n d v i e w s
The mPTP opens upon excessive calcium accumulation by mitochondria; ROS enhance the probability of its opening. Opening of the mPTP renders mitochondria totally incapable of producing ATP, performing many other functions such as calcium accumulation and retention, and maintaining ion homeostasis and osmotic balance. Severe swelling of mitochondria and damage to their ultrastructure frequently ensues after the mPTP opening, resulting in an obligatory decrease in the membrane potential and, eventually, in a loss of matrix solutes such as nicotinamite adenine dinucleotides and glutathione, which inhibits respiration. Moreover, a release of proapoptotic proteins such as cytochrome c may accompany the swelling and rupture of the outer mitochondrial membrane evoked by mPTP 9 , frequently resulting in cell death by apoptosis. The protein composition of the mPTP remains unknown 10, 11 .
Cyclosporine A is a strong inhibitor of calcium-induced mPTP opening. This compound binds CypD and inhibits its binding to the matrix side of the inner mitochondrial membrane, which is thought to be crucial for its activity as an mPTP modulator 10 . The mPTP in mitochondria isolated from CypDknockout mice is insensitive to cyclosporine A and shows a much higher calcium threshold than wild-type mitochondria 12, 13 , thereby proving the crucial role of CypD in controlling the mPTP opening probability.
Du et al. 6 provide evidence in mice that the interaction between Aβ and CypD promotes the opening of the mPTP, thereby causing neuronal injury and a decline in cognitive functions. They show that Aβ forms a complex with CypD in vivo and in vitro and that formation of this complex in vitro makes mitochondria more susceptible to mPTP opening. They further show that genetic ablation of CypD in a mouse model of Alzheimer's disease renders their brain mitochondria more resistant to mPTP openingand also substantially improves their cognitive abilities. These findings lend strong support to the role of mitochondrial dysfunction in Alzheimer's disease pathology, and they suggest that developing drugs targeting neuronal CypD may be a very promising therapeutic strategy to combat Alzheimer's disease.
Unfortunately, there are currently no safe CypD inhibitors specific to the brain that could be used to treat Alzheimer's disease in humans. CypD is ubiquitously expressed in mammalian tissues, and its functions probably extend beyond controlling the calcium sensitivity of the mitochondrial mPTP. Although cyclosporine A is very efficient in blocking the mPTP and also has a well established medical application as an immunosuppressant preventing tissue rejection in organ transplantation, it does not permeate the blood brain barrier well. It also shows severe adverse health effects such as nephrotoxicity and cardiac toxicity, although whether these effects are linked to its ability to inhibit mitochondrial CypD is not known.
Given the complexity and insufficient knowledge of mPTP composition and regulation, it is clear that some basic questions need to be answered first. Future challenges include understanding what proteins form the mPTP channel and what modulates the opening of mPTP in vivo and figuring out how to assess and modulate the mPTP in the brain. Answering these questions could lead to a safe and effective way to specifically inhibit mPTP in the brain of individuals with Alzheimer's disease and may provide a new avenue for treating this devastating disease.
